(HealthDay)—For children with high-risk group 3 medulloblastoma, therapy intensification with carboplatin improves event-free survival, according to a study published online July 22 in JAMA Oncology. Sarah E. S. Leary, M.D., from Seattle Children’s, and colleagues examined therapy intensification with carboplatin…